Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm Open-Label Multi-Center Study of Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

NCT07085039 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT07085039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07085039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm Open-Label Multi-Center Study of Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Lead sponsor
University of Pennsylvania
Phase
Phase 2
Overall status
Recruiting
Start date
December 18, 2025
Completion date
December 31, 2028
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castleman's disease (cd), idiopathic multicentric castleman's disease